|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012854,
umls-concept:C0021311,
umls-concept:C0023272,
umls-concept:C0032136,
umls-concept:C0033684,
umls-concept:C0181586,
umls-concept:C0871261,
umls-concept:C0949285,
umls-concept:C1423842,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1880497,
umls-concept:C1996904,
umls-concept:C2911692
|
|
pubmed:issue |
48
|
|
pubmed:dateCreated |
2009-11-2
|
|
pubmed:abstractText |
Canine visceral leishmaniasis is a serious public health concern in the Mediterranean basin since dogs are the main Leishmania infantum reservoir. However, there is not a vaccination method in veterinary use in this area, and therefore the development of a vaccine against this parasite is essential for the possible control of the disease. Previous reports have shown the efficacy of heterologous prime-boost vaccination with the pCIneo plasmid and the poxvirus VV (both Western Reserve and MVA strains) expressing L. infantum LACK antigen against canine leishmaniasis. As pCIneo-LACK plasmid contains antibiotic resistance genes, its use as a profilactic method is not recommended. Hence, the antibiotic resistance gene free pORT-LACK plasmid is a more suitable tool for its use as a vaccine. Here we report the protective and immunostimulatory effect of the prime-boost pORT-LACK/MVA-LACK vaccination tested in a canine experimental model. Vaccination induced a reduction in clinical signs and in parasite burden in the liver, an induction of the Leishmania-specific T cell activation, as well as an increase of the expression of Th1 type cytokines in PBMC and target organs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Protozoan,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Protozoan,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Protozoan,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/LACK antigen, Leishmania,
http://linkedlifedata.com/resource/pubmed/chemical/Leishmaniasis Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Protozoan Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, DNA
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1873-2518
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
12
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6695-703
|
|
pubmed:meshHeading |
pubmed-meshheading:19747996-Animals,
pubmed-meshheading:19747996-Antibodies, Protozoan,
pubmed-meshheading:19747996-Antigens, Protozoan,
pubmed-meshheading:19747996-Cytokines,
pubmed-meshheading:19747996-DNA, Protozoan,
pubmed-meshheading:19747996-Dog Diseases,
pubmed-meshheading:19747996-Dogs,
pubmed-meshheading:19747996-Female,
pubmed-meshheading:19747996-Immunization, Secondary,
pubmed-meshheading:19747996-Immunoglobulin G,
pubmed-meshheading:19747996-Leishmania infantum,
pubmed-meshheading:19747996-Leishmaniasis, Visceral,
pubmed-meshheading:19747996-Leishmaniasis Vaccines,
pubmed-meshheading:19747996-Liver,
pubmed-meshheading:19747996-Lymphocyte Activation,
pubmed-meshheading:19747996-Male,
pubmed-meshheading:19747996-Plasmids,
pubmed-meshheading:19747996-Protozoan Proteins,
pubmed-meshheading:19747996-Th1 Cells,
pubmed-meshheading:19747996-Vaccines, DNA
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
|
|
pubmed:affiliation |
Centro de Investigaciones Biológicas, Spanish Research Council, Ramiro de Maeztu 9, 28040 Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
